858121-96-7 Usage
Description
1-(BromoMethyl)-4-(trifluoroMethyl)cyclohexane is an organic compound with the chemical formula C9H14BrF3. It is a colorless liquid at room temperature and is insoluble in water. The presence of bromine and trifluoromethyl groups in its structure gives it unique chemical and physical properties, making it a valuable building block for the synthesis of more complex organic compounds.
Uses
Used in Chemical Reactions:
1-(BromoMethyl)-4-(trifluoroMethyl)cyclohexane is used as a solvent for various chemical reactions, facilitating the process and improving the efficiency of the reactions.
Used in Organic Synthesis:
1-(BromoMethyl)-4-(trifluoroMethyl)cyclohexane is used as a reagent in organic synthesis, contributing to the formation of desired products and aiding in the synthesis of complex organic compounds.
Used in Pharmaceutical Industry:
1-(BromoMethyl)-4-(trifluoroMethyl)cyclohexane is used as a building block in the pharmaceutical industry for the synthesis of pharmaceutical compounds, taking advantage of its unique chemical properties.
Used in Agrochemical Industry:
1-(BromoMethyl)-4-(trifluoroMethyl)cyclohexane is used in the agrochemical industry for the synthesis of agrochemical compounds, potentially contributing to the development of new pesticides or other agricultural products.
Check Digit Verification of cas no
The CAS Registry Mumber 858121-96-7 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,5,8,1,2 and 1 respectively; the second part has 2 digits, 9 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 858121-96:
(8*8)+(7*5)+(6*8)+(5*1)+(4*2)+(3*1)+(2*9)+(1*6)=187
187 % 10 = 7
So 858121-96-7 is a valid CAS Registry Number.
858121-96-7Relevant articles and documents
2,6,7 SUBSTITUTED PURINES AS HDM2 INHIBITORS
-
Page/Page column 82, (2014/08/20)
The present invention provides 2,6,7 substituted purines as described herein or a pharmaceutically acceptable salt thereof. The representative compounds are useful as inhibitors of the HDM2 protein. Also disclosed are pharmaceutical compositions comprising the above compounds and potential methods of treating cancer using the same.
